Impact Factor
3.41
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.45
303 total citations
h5-index
25
h5 depth signal
Cited share
76.3%
71 of 93
Total citations
303
Citation footprint
Metric signal
3.62
External metric anchor
Self-citation
0.7%
2 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
365
Canada
33
France
28
Germany
28
United Kingdom
28
Citing Fields of Research
Hematology
440
Immunology
107
Stem Cell Biology
84
Lymphomas
38
Genetics & Genomics
37
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,355
Articles tracked across the journal lifetime
Indexed publication set
93
71 cited publications
Last 12 months
48
4.4 publications/month
Open access share
18.8%
9 OA publications in the last year
Leading citing country
United States
365 citing publications
Leading citing field
Hematology
440 citing publications
Latest tracked publication
1 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1994-
v1n1, 1994-
Active Coverage
Research Focus & Classification
Indexed Subjects
Hematology
Broad Categories
Hematology
MeSH Descriptors
Blood
Hematologic Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/moh.0000000000000953
Open DOI
Editorial introductions
Was not provided for this article.
02
DOI 10.1097/moh.0000000000000950
Open DOI
Allogeneic haematopoietic stem cell transplantation: when will better measures lead to better survival?
Was not provided for this article.
03
DOI 10.1097/moh.0000000000000946
Open DOI
Prekallikrein: the catalytic crossroads of inflammation and thrombosis
Purpose of review: The contact activation pathway, historically considered dispensable for hemostasis, has re-emerged as a critical mediator of thromboinflammation. Plasma prekallikrein, through its activation to kallikrein, links coagul...
04
DOI 10.1097/moh.0000000000000947
Open DOI
Pregnancy after haematopoietic stem cell transplantation: likelihood, risks, and management
Purpose of review: Advances in haematopoietic stem cell transplantation (HSCT) have improved long-term survival, making fertility and reproductive health increasingly important aspects of survivorship. This review summarizes current evid...
05
DOI 10.1097/moh.0000000000000942
Open DOI
The life, function and death of platelets
Platelets, the smallest blood cells, weave through health and disease, their history profound, some of their functions yet to be revealed. Terminology often drifts, but by naming with precision, we illuminate understanding, guide newcome...
06
DOI 10.1097/moh.0000000000000955
Open DOI
Sickle cell disease and hematopoietic stem cell transplantation: donor expansion, gene-modified grafts and prenatal horizons
Purpose of review: To review advances from the past 18 months in allogeneic hematopoietic stem cell transplantation (HSCT) and autologous gene-modified stem cell transplantation for sickle cell disease (SCD), and to relate these developm...
07
DOI 10.1097/moh.0000000000000952
Open DOI
Second-line and salvage therapies for steroid-refractory acute graft-versus-host disease: an integrated synthesis of current evidence and clinical sequencing
Purpose of review: Acute graft-versus-host disease (aGVHD) remains a principal driver of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Fifty percent of patients fail to achieve durable respons...
08
DOI 10.1097/moh.0000000000000951
Open DOI
Proteomics in the discovery of biomarkers of major complications after allogeneic hematopoietic cell transplantation
Purpose of review: Allogeneic hematopoietic cell transplantation (allo-HCT) is complicated by life-threatening conditions whose prompt diagnosis is essential yet frequently delayed. This review examines proteomic approaches to biomarker ...
09
DOI 10.1097/moh.0000000000000949
Open DOI
Bridging TP53-mutated myelodysplastic syndrome/acute myeloid leukemia to transplant: is venetoclax part of the answer?
Purpose of review: TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) remain among the most challenging myeloid malignancies, with poor long-term outcomes despite allogeneic stem cell transplantation (HCT). Vene...
10
DOI 10.1097/moh.0000000000000948
Open DOI
Maintenance therapy after allogeneic stem cell transplantation for relapse prevention in myeloid malignancies
Purpose of review: Relapse remains the leading cause of treatment failure after allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and outcomes after relapse are poor...
Bibliographical & Catalog Notes
Title from cover.
Each issues has also a distinctive title.
Includes a section called: Bibliography of the current world literature.
Also issued online.
Complemented by: Current world literature.
Vol. 1, no. 1 (JAN 1994)19960724 Notice published Printed on acid-free paper